<DOC>
	<DOCNO>NCT01822691</DOCNO>
	<brief_summary>The primary purpose research study ass whether participant 's disease , Myelodysplastic Syndromes ( MDS ) , respond favorably INCB024360 . The study also evaluate long-term outcome participant 's disease finish take INCB024360 .</brief_summary>
	<brief_title>Phase II INCB024360 Study Patients With Myelodysplastic Syndromes ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Confirmed diagnosis myelodysplastic syndrome ( MDS ) Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Adequate organ function : Total bilirubin ≤ 1.5 × Upper Limit Normal ( ULN ) Aspartic transaminase ( AST ) /alanine transaminase ( ALT ) ≤ 2.5 × ULN Creatinine ≤ 2 × ULN Creatinine clearance &gt; 30 mL/min ( use Cockcroft Gault Equation ) Females childbearing potential must negative urine serum pregnancy test Screening . Women childbearing potential men must agree use adequate contraception ( surgical tubal ligation vasectomy , doublebarrier method birth control condom spermicide conjunction use intrauterine device ( IUD ) diaphragm ; sexual abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant , male impregnate female partner , participate study , he/she inform treat physician immediately . Ability understand willingness sign write informed consent document Prior MDS therapy within 4 week first dose study medication . For erythroid stimulating agent growth factor : prior therapy epoetin ( Procrit ) GCSF ( neupogen ) GMCSF ( leukine ) within 2 week first dose study medication . Has participate trial receipt investigational study drug occur within 28 day . Has undergone stem cell , bone marrow solid organ transplant . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit investigator opinion compliance study requirement History hepatitis positive serology follow : Hepatitis B ( HepB ) screen test require : HepB SAg ( hepatitis B surface antigen ) ; AntiHepB SAg ( antibody hepatitis B surface antigen ) ; AntiHepatitis B core IgG ( antibody hepatitis B core antigen ) ; AntiHepatitis B core IgM antibody Note : Subjects prior history hepatitis B infection vaccinate hepatitis B positive antiHepB SAg test evidence prior exposure may participate trial . Hepatitis C screening require : antibody hepatitis C virus ( HCVantibody ) ; HCVRNA ( serum test circulate virus , base detect RNA ) Known history human immunodeficiency virus ( HIV ) Is receive compound know potent inducer inhibitor CYP3A4 Being treat monoamine oxidase inhibitor ( MAOI ) , drug significant monoamine oxidase inhibitory activity ( meperidine , linezolid , methylene blue ) within 3 week prior screen Has , investigator assessment , active autoimmune process rheumatoid arthritis , psoriasis , multiple sclerosis , inflammatory bowel disease , etc . receive therapy autoimmune disease . Subjects vitiligo , hypothyroidism eczema may enrol approval sponsor . Receiving immunologically base treatment reason , include chronic use systemic steroid dose ≥ 7.5 mg/day prednisone equivalent ; use inhaled topical steroid acceptable . Prior malignancy MDS subject disease free ≤ 3 year , except treat cure basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ cervix . Use UGT1A9 inhibitor include : diclofenac , imipramine , ketoconazole , mefenamic acid , probenecid screen followup period . Have prior Serotonin Syndrome Any unresolved toxicity great Grade 2 previous anticancer therapy , except stable chronic toxicity expect resolve , peripheral neurotoxicity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>myelodysplastic syndrome ( MDS )</keyword>
	<keyword>neoplastic stem cell disorder</keyword>
	<keyword>refractory cytopenia</keyword>
	<keyword>dysplastic morphological feature</keyword>
	<keyword>acute myeloid leukemia ( AML )</keyword>
</DOC>